Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Monday, February 10, 2025 1 min read
Key Takeaway: Invivyd, Inc. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. Marc Elia, the Chairman of the Board, will lead the presentation at 1:20 PM ET. The event will be accessible via a live webcast on the company's investor relations website. Invivyd focuses on developing antibodies to combat serious viral infectious diseases and has received emergency use authorization for one of its monoclonal antibody candidates.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is presenting at a prominent conference, highlighting its visibility in the industry.
  • The company has received EUA from the U.S. FDA for a monoclonal antibody, showcasing its innovative capabilities.
  • Invivyd's proprietary technology platform is unique and may lead to significant advancements in biopharmaceuticals.

Full Press Release Details

WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The presentation is set to take place at 1:20 PM ET on Wednesday, February 12th. The live webcast link will be available in the investor section of the company's website at https://investors.invivyd.com and will be archived for approximately 90 days following the event.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
investors@invivyd.com

Frequently Asked Questions

When will Marc Elia present at the Oppenheimer Conference?

Marc Elia will present on February 12th at 1:20 PM ET.

Where can I watch the live webcast of Invivyd's presentation?

The live webcast will be available on Invivyd's investor website.

What is Invivyd's focus as a biopharmaceutical company?

Invivyd specializes in protection against serious viral infectious diseases.

What authorization has Invivyd received from the FDA?

Invivyd received emergency use authorization for a monoclonal antibody.

How long will the webcast be archived after the event?

The webcast will be archived for approximately 90 days.

Tags: IVVD Viatris Investor Conferences Healthcare Invivyd monoclonal antibodies Oppenheimer conference biopharmaceuticals SARS-CoV-2
Last updated: Feb 10, 2025